VANCOUVER, Nov. 14 /PRNewswire/ - Sirius Genomics, a developer of pharmacogenomic tests, announced the appointment of three new members to its Board of Directors.
New Board members include Dr. Heiner Dreismann, Dr. Chris Fibiger and Mr. Patrick Terry.
Previously, Dr. Dreismann served as President and CEO of Roche Molecular Diagnostics, the world's leading molecular diagnostics company. During a six-year period there, Dr. Dreismann spearheaded global marketing and sales efforts which resulted in the doubling of the overall sales of the company. Prior to Roche, Dr. Dreismann was head of the Integration Office for Roche Diagnostics where he managed the merger of Boehringer Mannheim with Roche Diagnostics. Additionally, Dr. Dreismann is currently on the boards of several public and private biotech and diagnostic companies.
Dr. Fibiger was previously the Vice President and Global Head of Neuroscience at Amgen. He was responsible for Amgen's worldwide internal Neuroscience discovery efforts, as well as the evaluation and implementation of collaborative efforts, alliances and licensing agreements with external partners. Before joining Amgen in 2003, Dr. Fibiger served as Vice President of Neuroscience Discovery Research and Clinical Investigation at Eli Lilly and Company.
Mr. Patrick Terry is the newest director to be appointed to the Company's Board. In 2000, Mr. Terry and a group of prominent leaders in the fields of genomics, bioinformatics and biotechnology founded Genomic Health, a pioneering personalized medicine company. Mr. Terry is a social entrepreneur who has founded a series of innovative philanthropic, research, and commercial organizations based on the life sciences, applied technology, and social-network theory. Some of Mr. Terry's activities include leadership positions on numerous trade associations, professional societies, corporate boards, and federal advisory bodies. Mr. Terry has dedicated his career to helping people and advancing a patient-centered perspective in research and translational medicine.
"We are extremely pleased to have these outstanding individuals join our Board. Their global expertise and deep experience in molecular diagnostics, drug development and commercialization will be critical to Sirius as we continue to grow our company. Our Board and management team has become an international group containing the highest caliber people in their fields. This is the right group of people needed for Sirius to be a global competitor in the rapidly growing field of personalized medicine." stated Dr. Brad Popovich, President and CEO of Sirius Genomics.
About Sirius Genomics: www.siriusgenomics.com
Sirius Genomics is a drug-enabling company that excels at developing pharmacogenomic (PGx) tests that lead to better patient outcomes through personalized medicine. Sirius' business focus is on generating value through improving the safety and effectiveness of pharmaceutical compounds. The Company's expert medical and business team correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable PGx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection.
This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.
SOURCE Sirius Genomics Inc.